Minimal residual disease is highly predictive of outcome in myeloma: results from MRC Myeloma IX

被引：0

作者：

Owen, R. G. ^{[1
]}

de Tute, R. M. ^{[1
]}

Child, J. A. ^{[2
]}

Davies, F. E. ^{[3
]}

Gregory, W. ^{[2
]}

Bell, S. ^{[2
]}

Szubert, A. ^{[2
]}

Navarro-Coy, N. ^{[2
]}

Drayson, M. T. ^{[4
]}

Feyler, S. ^{[5
]}

Ross, F. ^{[6
]}

Cook, G. ^{[1
]}

Jackson, G. H. ^{[7
]}

Morgan, G. J. ^{[3
]}

Rawstron, A. C. ^{[1
]}

机构：

[1] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England

[2] Univ Leeds, CTRU, Leeds LS2 9JT, W Yorkshire, England

[3] Inst Canc Res, London SW3 6JB, England

[4] Univ Birmingham, Birmingham B15 2TT, W Midlands, England

[5] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield, W Yorkshire, England

[6] Wessex Reg Cytogenet Unit, Salisbury, Wilts, England

[7] Univ Newcastle, Newcastle Upon Tyne, Tyne & Wear, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：12 / 13

页数：2

共 50 条

[1] Zoledronic acid in myeloma: MRC Myeloma IX
Rajkumar, S. Vincent
LANCET, 2010, 376 (9757): : 1965 - 1966
[2] Minimal residual disease predicts outcome in transplant ineligible myeloma patients: Results from the UK NCRI Myeloma XI trial
de Tute, R. M.
Rawstron, A. C.
Cairns, D.
Pawlyn, C.
Davies, F.
Collett, C.
Jones, J.
Kaiser, M.
Chalmers, A.
Striha, A.
Cook, G.
Russell, N.
Drayson, M. T.
Gregory, W. M.
Jackson, G. H.
Morgan, G. J.
Owen, R. G.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 105 - 105
[3] MRC Myeloma IX: Preliminary Results from The Intensive Pathway Study
Owen, R. G.
Child, J. A.
Jackson, G. H.
Davies, F. E.
Drayson, M. T.
Ross, F. M.
Gregory, W. M.
Szubert, A. J.
Bell, S. E.
Heatley, F.
Navarro-Coy, N.
Rawstron, A. C.
Morgan, G. H.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S84 - S85
[4] Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Rawstron, Andy C.
Child, J. Anthony
de Tute, Ruth M.
Davies, Faith E.
Gregory, Walter M.
Bell, Sue E.
Szubert, Alexander J.
Navarro-Coy, Nuria
Drayson, Mark T.
Feyler, Sylvia
Ross, Fiona M.
Cook, Gordon
Jackson, Graham H.
Morgan, Gareth J.
Owen, Roger G.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2540 - +
[5] MRC Myeloma IX: Preliminary Results from the Non-Intensive Study
Owen, R. G.
Morgan, G. J.
Jackson, H.
Davies, F. E.
Drayson, M. T.
Ross, F. M.
Navarro-Coy, N.
Gregory, W. M.
Szubert, A. J.
Rawstron, A. C.
Bell, S. E.
Heatley, F.
Child, J. A.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S85 - S85
[6] Minimal Residual Disease in Multiple Myeloma
Munshi, Nikhil C.
Anderson, Kenneth C.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2523 - 2526
[7] Minimal residual disease in multiple myeloma
Moukalled, Nour
Malard, Florent
Bazarbachi, Ali
Mohty, Mohamad
PRESSE MEDICALE, 2025, 54 (01):
[8] Minimal residual disease for multiple myeloma
Avet-Loiseau, Herve
Corre, Jill
HEMATOLOGIE, 2019, 25 : 36 - 39
[9] Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial
de Tute, Ruth Mary
Rawstron, Andy C.
Cairns, David A.
Pawlyn, Charlotte
Davies, Faith E.
Collett, Corinne
Kaiser, Martin F.
Jones, John R.
Waterhouse, Anna
Striha, Alina
Cook, Gordon
Jenner, Matthew W.
Russell, Nigel H.
Drayson, Mark T.
Gregory, Walter M.
Jackson, Graham H.
Morgan, Gareth J.
Owen, Roger G.
BLOOD, 2016, 128 (22)
[10] The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Morgan, Gareth J.
Gregory, Walter M.
Davies, Faith E.
Bell, Sue E.
Szubert, Alexander J.
Brown, Julia M.
Coy, Nuria N.
Cook, Gordon
Russell, Nigel H.
Rudin, Claudius
Roddie, Huw
Drayson, Mark T.
Owen, Roger G.
Ross, Fiona M.
Jackson, Graham H.
Child, J. Anthony
BLOOD, 2012, 119 (01) : 7 - 15

← 1 2 3 4 5 →